Keros Therapeutics, Inc.
KROSCIK 0001664710 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR
At a glance · FY2025 (Q4)
Quality Score
Quality score
6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration
- Profitability48ROIC 14.6% (10% = solid, 20%+ = moat)
- Liquidity100Current Ratio 15.45 (above 1.5 = solid)
- Leverage0Insufficient data
- Efficiency24Asset Turnover 0.51x (1.0+ = capital-efficient)
- Growth0Insufficient data
- Margin Trend0Insufficient data
Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.
DCF intrinsic value
DCF intrinsic value
two-stage Gordon modelProject KROS's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.
Trailing CAGR unavailable; default 8%
10% is a common all-equity benchmark for US large-caps
Should be ≤ long-run GDP growth (~2.5% nominal)
5-year explicit projection + perpetuity terminal
| Year | Projected FCF | Discounted PV |
|---|---|---|
| +1 | $114M | $104M |
| +2 | $124M | $102M |
| +3 | $133M | $100M |
| +4 | $144M | $98M |
| +5 | $156M | $97M |
| Terminal | $2.13B | $1.32B |
DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.
Capital allocation · trailing 4 quarters
how the company spent its cashBalance sheet · 2025-12-31
latest filed snapshotRecent performance · 28 quarters
Drill down
KROS Sankey
See Keros Therapeutics, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.
Open SankeyKROS Charts
28 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.
Open ChartsKROS Key Metrics
EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.
Open Key Metrics